Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
To determine the efficacy (as measured by progression-free survival \[PFS\] rate at 8 weeks) of regorafenib in subjects with metastatic colorectal cancer (CRC) whose disease is refractory to standard therapies and who were never exposed to antiangiogenic therapy.
Colorectal Neoplasms
DRUG: Regorafenib (Stivarga, BAY73-4506)
Percentage of participants without disease progression or death at the end of 8 weeks, At week 8
Progression-Free Survival (PFS), PFS is defined as the date from the first dose of regorafenib until radiologic and/or clear clinical progression or death from any cause, whichever comes first., Approximately 2 months|Overall Survival (OS), OS is defined as the date from the first dose of regorafenib until death by any cause., Approximately 2 months|Overall Response Rate (ORR), ORR is defined as the proportion of subjects with the best tumor response (confirmed PR or CR) that is achieved during or within 30 days after therapy., Approximately 2 months|Disease Control Rate (DCR), DCR is defined as the proportion of subjects who have a best response rating over the whole duration of the study of CR, PR, or SD., Approximately 2 months|Metabolic response measured by [18F] fluorodeoxyglucose positron emission tomography (FDG PET), Approximately 2 months|Percentage of participants with grade 1 or higher adverse events, using NCI Common Terminology Criteria for Adverse Events (CTC-AE) Version 4.03, Approximately 2 months
To determine the efficacy (as measured by progression-free survival \[PFS\] rate at 8 weeks) of regorafenib in subjects with metastatic colorectal cancer (CRC) whose disease is refractory to standard therapies and who were never exposed to antiangiogenic therapy.